Literature DB >> 27713608

Aliskiren Inhibits Neointimal Matrix Metalloproteinases in Experimental Atherosclerosis.

Tao-Cheng Wu1, Chiu-Yang Lee2, Shing-Jong Lin3, Jaw-Wen Chen4.   

Abstract

BACKGROUND: The renin-angiotensin system (RAS) plays an important role in atherosclerosis. Acting via the angiotensin II receptor, type 1, oxidative stress increases and contributes to endothelial dysfunction and vascular inflammation. Renin exerts effects through a renin receptor causing an increase in the efficiency of angiotensinogen cleavage and facilitates angiotensin II (Ang II) generation and action on cell surfaces. Ang II enhances proliferation and migration of vascular smooth muscle cells, indicating a direct involvement of the RAS in smooth muscle cell proliferation during neointimal formation. Aliskiren, a direct renin inhibitor, is a new oral antihypertensive drug. However, the role of the direct renin inhibitor in neointimal formation and vascular matrix metalloproteinases remains unclear.
METHODS: To investigate the effects of aliskiren on the expression of vascular matrix metalloproteinases, we evaluated the aortic neointimal formation of high-cholesterol-fed animals after vascular injury in vivo and the cellular function of the tumor necrosis factor-α stimulated human aortic smooth muscle cells in vitro. Thereafter, we evaluated vascular expression (by western blot), activity (by gelatin zymography) and molecular pathway.
RESULTS: In this study we demonstrated that aliskiren reduced neointimal hyperplasia in hypercholesterolemic rabbits after vascular injury and the expression of matrix metalloproteinases in the neointima. Aliskiren also inhibited the expression and activities of matrix metalloproteinases on tumor necrosis factor-α (TNF-α)-stimulated human aortic smooth muscle cells via the mitogen-activated protein kinase pathway.
CONCLUSIONS: The present study showed that aliskiren inhibited the expression of vascular matrix metalloproteinases. With these results, we have better clarified the potential role of renin inhibitors in human atherosclerosis.

Entities:  

Keywords:  Matrix metalloproteinases; Neointimal hyperplasia; Renin inhibitor

Year:  2016        PMID: 27713608      PMCID: PMC5052478          DOI: 10.6515/acs20151012c

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  17 in total

1.  Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor.

Authors:  Alan Daugherty; Debra L Rateri; Hong Lu; Tadashi Inagami; Lisa A Cassis
Journal:  Circulation       Date:  2004-12-13       Impact factor: 29.690

2.  Renin inhibition reduces atherosclerotic plaque neovessel formation and regresses advanced atherosclerotic plaques.

Authors:  Hongxian Wu; Xian Wu Cheng; Lina Hu; Chang-Ning Hao; Mutsuharu Hayashi; Kyosuke Takeshita; Mohammad Shoaib Hamrah; Guo-Ping Shi; Masafumi Kuzuya; Toyoaki Murohara
Journal:  Atherosclerosis       Date:  2014-10-30       Impact factor: 5.162

3.  Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.

Authors:  Alice Stanton; Chris Jensen; Juerg Nussberger; Eoin O'Brien
Journal:  Hypertension       Date:  2003-11-03       Impact factor: 10.190

4.  Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program.

Authors:  Hae-Young Lee; Byung-Hee Oh
Journal:  Expert Rev Cardiovasc Ther       Date:  2009-03

5.  Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice.

Authors:  Sven Wassmann; Thomas Czech; Martin van Eickels; Ingrid Fleming; Michael Böhm; Georg Nickenig
Journal:  Circulation       Date:  2004-07-26       Impact factor: 29.690

6.  Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice.

Authors:  Hong Lu; Debra L Rateri; David L Feldman; Richard J Charnigo; Akiyoshi Fukamizu; Junji Ishida; Elizabeth G Oesterling; Lisa A Cassis; Alan Daugherty
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

7.  Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Authors:  Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

8.  Mechanism of inhibition of neointimal formation by the angiotensin-converting enzyme inhibitor cilazapril. A study in balloon catheter-injured rat carotid arteries.

Authors:  J Fingerle; R M Müller; H Kuhn; M Pech; H R Baumgartner
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-11       Impact factor: 8.311

9.  Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.

Authors:  Toshio Imanishi; Hiroto Tsujioka; Hideyuki Ikejima; Akio Kuroi; Shigeho Takarada; Hironori Kitabata; Takashi Tanimoto; Yasuteru Muragaki; Seiichi Mochizuki; Masami Goto; Kiyoshi Yoshida; Takashi Akasaka
Journal:  Hypertension       Date:  2008-07-21       Impact factor: 10.190

10.  Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy.

Authors:  Waymon Drummond; Mark A Munger; Mohammed Rafique Essop; Mojdeh Maboudian; Mahmudul Khan; Deborah L Keefe
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-10       Impact factor: 3.738

View more
  1 in total

Review 1.  Renin-Angiotensin System in Pathogenesis of Atherosclerosis and Treatment of CVD.

Authors:  Anastasia V Poznyak; Dwaipayan Bharadwaj; Gauri Prasad; Andrey V Grechko; Margarita A Sazonova; Alexander N Orekhov
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.